Arcturus Therapeutics Holdings Inc. (ARCT)
| Market Cap | 351.02M +15.2% |
| Revenue (ttm) | 29.37M -76.0% |
| Net Income | -93.28M |
| EPS | -3.33 |
| Shares Out | 28.42M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 78,314 |
| Open | 12.07 |
| Previous Close | 12.07 |
| Day's Range | 12.03 - 12.30 |
| 52-Week Range | 5.50 - 17.96 |
| Beta | 2.48 |
| Analysts | Strong Buy |
| Price Target | 23.80 (+92.71%) |
| Earnings Date | Nov 5, 2026 |
About ARCT
Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system. The company also develops ARCT-032 (LUNAR-CF), an mRNA therapeutic candidate for cystic fibrosis that is in Phase 2 clinical development; and ARCT-810 (LUNAR-OTC), which is in Phase 2 clinical development to address ornithine transcarbamylase (OTC) deficiency. In additi... [Read more]
Financial Performance
In 2025, ARCT's revenue was $82.03 million, a decrease of -46.14% compared to the previous year's $152.31 million. Losses were -$65.78 million, -18.73% less than in 2024.
Financial StatementsAnalyst Summary
According to 13 analysts, the average rating for ARCT stock is "Strong Buy." The 12-month stock price target is $23.8, which is an increase of 92.71% from the latest price.
News
Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 5, 2026
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #65Roses--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and ...
Arcturus Therapeutics price target lowered to $20 from $23 at BTIG
BTIG lowered the firm’s price target on Arcturus Therapeutics (ARCT) to $20 from $23 and keeps a Buy rating on the shares after the company announced interim OTC deficiency Phase…
Arcturus Therapeutics upgraded to Buy from Neutral at Citi
Citi upgraded Arcturus Therapeutics (ARCT) to Buy from Neutral with a price target of $20, up from $8. The firm says ARCT-810’s clinical activity and ARCT-2601’s “bridge” improve the company’s…
Arcturus Therapeutics upgraded to Buy from Neutral at Citi
Citi upgraded Arcturus Therapeutics (ARCT) to Buy from Neutral with a $20 price target
Arcturus Therapeutics Holdings Transcript: Status update
Phase II data show ARCT-810 is safe, well-tolerated, and effective in normalizing ammonia and reducing glutamine in OTC deficiency, even with increased protein intake. LUNAR 2.0 enables higher protein expression, supporting lower, less frequent dosing. FDA supports integrating ARCT-2601 into the study, with pivotal pediatric trials and pipeline expansion planned.
Arcturus Therapeutics Holdings Press release: Status update
Arcturus Therapeutics Holdings issued a press release on September 23, 2026, disclosing material business information to investors.
Arcturus Therapeutics Holdings Slides: Status update
Arcturus Therapeutics Holdings has posted slides in relation to its latest quarterly earnings report, which was published on September 23, 2026.
Arcturus Therapeutics announces interim OTC deficiency Phase 2 results
The company states: “Arcturus Therapeutics (ARCT) announced encouraging interim Phase 2 results from ARCT-810 in ornithine transcarbamylase deficiency and introduced LUNAR 2.0, the Company’s next-gene...
Arcturus Therapeutics Announces Interim OTC Deficiency Phase 2 Results and Introduces LUNAR 2.0™ Next-Generation mRNA Delivery Platform
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #65Roses--Arcturus Therapeutics Holdings Inc. (the “Company,” “Arcturus,” Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and ...
Arcturus Therapeutics to Present Ornithine Transcarbamylase (OTC) Deficiency Phase 2 Clinical Data and Provide Update on mRNA Liver Therapeutics Platform
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #65Roses--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and ...
Arcturus Therapeutics Holdings Transcript: H.C. Wainwright 28th Annual Global Investment Conference
The session highlighted differentiated mRNA technologies, a robust rare disease pipeline, and regained global control of a leading COVID vaccine. Key near-term milestones include a phase II data readout for OTC deficiency and a pivotal phase III decision for the CF program, both with significant commercial and regulatory implications.
Arcturus Therapeutics Holdings Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
Upcoming data readouts for liver (OTC deficiency) and lung (cystic fibrosis) mRNA programs are expected to shape the next year, with regulatory clarity and potential phase III advancement. The self-amplifying mRNA platform continues to generate revenue and attract interest for broader applications.
Arcturus Therapeutics Holdings Transcript: Citigroup’s Biopharma Back to School Summit 2026
Upcoming milestones include a phase II data and regulatory update for the OTC deficiency program and a Q4 go/no-go decision for the CF inhaled mRNA therapy, which could unlock $40M in funding. Both programs leverage advanced mRNA technologies and are supported by positive regulatory feedback and innovative partnerships.
Arcturus Therapeutics price target raised to $41 from $20 at Roth Capital
Roth Capital raised the firm’s price target on Arcturus Therapeutic (ARCT) s to $41 from $20 and keeps a Buy rating on the shares. Six months into the 12-week Cohort…
Arcturus Therapeutics to Participate in Upcoming Investor Conferences
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #65Roses--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and ...
Arcturus Therapeutics Holdings Transcript: Canaccord Genuity's 46th Annual Growth Conference
The company is advancing two flagship mRNA programs for cystic fibrosis and OTC deficiency, both nearing phase III with significant unmet needs and commercial potential. A unique Thermo Fisher partnership supports CF development, while strong cash reserves and regained vaccine rights provide strategic flexibility.
Arcturus Therapeutics price target lowered to $20 from $21 at Canaccord
Canaccord lowered the firm’s price target on Arcturus Therapeutics (ARCT) to $20 from $21 and keeps a Buy rating on the shares. The firm said in its 2Q26 report that…
Arcturus Therapeutics Holdings Earnings Call Transcript: Q2 2026
Phase II studies for ARCT-032 and ARCT-810 advanced, with ARCT-810 completing enrollment and dosing. Regained global rights to the KOSTAIVE vaccine and broader saRNA platform, strengthening strategic control. Cash runway extends through 2028, supporting key milestones.
Arcturus Therapeutics Holdings Earnings release: Q2 2026
Arcturus Therapeutics Holdings released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Arcturus Therapeutics Holdings Quarterly report: Q2 2026
Arcturus Therapeutics Holdings has published its Q2 2026 quarterly earnings report on August 6, 2026.
Arcturus Therapeutics Announces Second Quarter 2026 Financial Results and Pipeline Progress
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #65Roses--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and ...
Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on Aug 6, 2026
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #65Roses--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and ...
Arcturus Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #65Roses--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and ...
Arcturus, Thermo Fisher deal adds support to ARCT-032 exposure, says Roth
Roth Capital analyst Adam Walsh keeps a Buy rating and $20 price target on shares of Arcturus Therapeutics (ARCT). The Thermo Fisher (TMO) collaboration on ARCT-032 Phase 3 is viewed…
Arcturus announces collaboration with Thermo Fisher to advance ARCT-032
Arcturus Therapeutics (ARCT) announced a strategic collaboration with Thermo Fisher Scientific (TMO) to help support the Phase 3 development and potential commercialization of ARCT-032, Arcturus’ inve...